Sharenet Sites 
Sharenet Sites
Index Change Advice - 20161007 Aspen Pharmacare Free Float Update
Aspen Pharmacare Holdings (South Africa):
Investability Weight Change
FTSE/JSE Africa Index Series
29 September 2016
Following the receipt of updated shareholder information for Aspen Pharmacare Holdings (South Africa,
constituent) as a result of a secondary offering, please see details of affected indexes and effective dates
below:
Effective From
Index Change
Start of Trading
FTSE/JSE Top 40 (J200) Aspen Pharmacare Holdings (South 07 October 2016
Africa, ZAE000066692, B09C0Z1) will
remain in the index with an unchanged
shares in issue total of 454,779,457 and
an increased investability weighting of
79%.
FTSE/JSE All Share (J203) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE Large Cap Index (J205) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE Large and Mid Cap Index Aspen Pharmacare Holdings will remain 07 October 2016
(J206) in the index as detailed above.
FTSE/JSE Industrial 25 (J211) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE Financial & Industrial 30 Aspen Pharmacare Holdings will remain 07 October 2016
(J213) in the index as detailed above.
FTSE/JSE Equally Weighted Top 40 Aspen Pharmacare Holdings will remain 07 October 2016
Index (J2EQ) in the index as detailed above.
FTSE/JSE Equally Weighted Aspen Pharmacare Holdings will remain 07 October 2016
Industrial 25 Index (J5EQ) in the index as detailed above.
FTSE/JSE RAFI All Share Index Aspen Pharmacare Holdings will remain 07 October 2016
(J263) in the index as detailed above.
FTSE/JSE RAFI All Share Capped Aspen Pharmacare Holdings will remain 07 October 2016
Index (J283) in the index as detailed above.
FTSE/JSE Capped Top 40 (J300) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
Effective From
Index Change
Start of Trading
FTSE/JSE Capped All Share (J303) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE Style (J330 and J331) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE Shariah Top 40 Index Aspen Pharmacare Holdings will remain 07 October 2016
(J140) in the index as detailed above.
FTSE/JSE Capped Shariah Top 40 Aspen Pharmacare Holdings will remain 07 October 2016
Index (J141) in the index as detailed above.
FTSE/JSE All Share Shariah (J143) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE RAFI 40 (J260) Aspen Pharmacare Holdings will remain 07 October 2016
in the index as detailed above.
FTSE/JSE Shareholder Weighted All Aspen Pharmacare Holdings will remain 07 October 2016
Share (J403) in the index as detailed above.
FTSE/JSE Shareholder Weighted Aspen Pharmacare Holdings will remain 07 October 2016
Top 40 (J400) in the index as detailed above.
FTSE/JSE Shareholder Weighted Aspen Pharmacare Holdings will remain 07 October 2016
Industrial 25 Index (JSZ1) in the index as detailed above.
FTSE/JSE Shareholder Weighted Aspen Pharmacare Holdings will remain 07 October 2016
Financial & Industrial 30 Index in the index as detailed above.
(JSZ3)
FTSE/JSE Responsible Investment Aspen Pharmacare Holdings will remain 07 October 2016
(J113) in the index as detailed above.
For further information or general enquiries please contact us at info@ftse.com or indices@jse.co.za or call:
Client Services in UK: Tel: +44 (0) 20 7866 1810
Client Services in EMEA: Tel: +44 (0) 20 7866 1810
Client Services in US: New York: (Domestic) + 1 888 747 FTSE (3873) / (International): +1 212 314 1139
Client Services in Asia Pacific: Hong Kong: + 852 2164 3333 Australia:(Domestic Toll-Free) + 1800 653 680 / (International) + 61
(2) 9293 2864 Japan + 81 (3) 3581 2764
JSE Limited: Tel: +27 11 520 7137
Alternatively please visit our website at www.ftse.com or www.ftsejse.co.za
Terms of Use | Copyright © FTSE
Date: 29/09/2016 05:20:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
